I don't own it, but the NFTRH+ segment in NFTRH 464 noted... "Meanwhile, old friend AMGN is looking interesting these days; somewhat similar to how ABBV looked early this year.…
You could say GILD replaced ABBV after I took its profit and now ABBV is back after I took GILD's profit. It may sound slick, but it is really just…
Back in April of this year we did an NFTRH+ on BioPharma ABBV and its amazingly similar setup to 2016's NFTRH+ pick, LRCX. The original target was noted as 84,…
Less than 3 bucks from target #1 (75), I am taking the profit here. ABBV is very overbought as it led the momentum that recently whipped up in the sector…
Unlike Semi and Tech, certain items that have been relatively weak are now strengthening. Financials, Materials and Healthcare (ex-medical devices, which had been booming). It seems obvious that the big…
[edit] per the weekly report's NFTRH+ Notes segment, we have introduced an initial target of 75 and extended the best target to a less conservative 88 from 84. Here is…